Multivalent hiv vaccine boost compositions and methods of use
AssigneeGeoVax, Inc.
InventorHarriet Robinson
Life of this patent
Estimating the term…
Abstract
Compositions and methods of use are provided to boost a primed immune response to HIV. More specifically, the present invention relates to vaccine compositions comprising an HIV-protein boost or an MVA-expressed Env protein and methods of use. Exemplary HIV proteins for protein boosts include proteins such as gp120 proteins B.63521A11mutC and full-length single chain (FLSC), which has been modified to stabilize a CD4-induced Env structure. Exemplary MVAs expressing secreted Methods of administration and dosing regimens are also provided.
Claims15
1-37. (canceled)
The method of claim 1, wherein the first MVA vector is MVA/HIV62B.
A method for inducing an immune response to a human immunodeficiency virus (HIV) comprising administering to a human in need thereof:
- i) a prime vaccination comprising an effective amount of a vector encoding HIV antigens that, when expressed, are displayed on virus-like particles;
- and
- ii) a boost vaccination comprising
- a) an effective amount of a first modified vaccinia Ankara (MVA) vector encoding a membrane-bound HIV envelope (Env) protein that, when expressed, is displayed on virus-like particles, and,
- b) an effective amount of a second modified vaccinia Ankara (MVA) vector encoding an HIV gp-140 protein.
The method of claim 1, wherein the HIV gp140 is ADA gp140.
The method of claim 1, wherein the prime vaccination vector encoding HIV antigens is pGA2/JS7.
The method of claim 1, wherein the boost vaccination is administered 8 weeks after a last prime vaccination.
The method of claim 1, wherein a first prime vaccination is administered at 0 weeks and a second prime vaccination is administered at 8 weeks.
The method of claim 1, wherein the boost vaccination is administered at least 2 times.
The method of claim 1, wherein the boost vaccination is administered at week 16, week 24, and week 40 after administration of a first prime vaccination.
A method for boosting an immune response to a human immunodeficiency virus (HIV) comprising administering to a human in need thereof a boost vaccination comprising:
- a) an effective amount of a first modified vaccinia Ankara (MVA) vector encoding a membrane-bound HIV envelope (Env) protein that, when expressed, is displayed on virus-like particles, and,
- b) an effective amount of a second modified vaccinia Ankara (MVA) vector encoding an HIV gp-140 protein,
- wherein, prior to the administration of the boost vaccination, the human has previously been administered one or more prime vaccinations comprising an HIV antigen.
The method of claim 8, wherein the first MVA vector is MVA/HIV62B.
The method of claim 8, wherein the HIV gp140 is ADA gp140.
The method of claim 8, wherein the boost vaccination is administered 8 weeks after a last prime vaccination.
The method of claim 8, wherein the boost vaccination is administered at least 2 times.
The method of claim 8, wherein the boost vaccination is administered at week 16, week 24, and week 40 after administration of a first prime vaccination.
Dependencies are inferred from the claim text.